1-6 of 6
Sumeet Ambarkhane, MD MBBS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Eva González-Barca, MD PhD, Johannes Duell, MD, Federica Cavallo, Juan-Manuel Sancho, MD PhD, Zsolt Nagy, MD PhD, Pau Abrisqueta, MD PhD, Carlos Panizo, MD PhD, Marinela Augustin, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD, Nagesh Kalakonda, MD, Gilles Salles, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-140294
Published: 2020
Journal Articles

Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Gilles Salles, MDPhD, Budhaditya Goswami, MD, Vincenzo Bagnardi, Debarshi Dey, Mark Winderlich, PhD, Sumeet Ambarkhane, MD MBBS, Dan Huang, Grzegorz S. Nowakowski, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-140398
Published: 2020
Journal Articles

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, Anna Marina Liberati, MD, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MDPhD, Gianluca Gaidano, Pau Abrisqueta, MD PhD, Marc André, MD, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles Salles, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–21.
https://doi.org/10.1182/blood-2020-140314
Published: 2020
Journal Articles

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, MD, Kami J. Maddocks, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MD PhD, Anna Marina Liberati, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MD PhD, Gianluca Gaidano, MD PhD, Pau Abrisqueta, MD PhD, Marc André, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles A. Salles, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1582.
https://doi.org/10.1182/blood-2019-122573
Published: 2019
Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Georg Hess, Gianluca Gaidano, MD PhD, Mariano Provencio, MD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD, Kami J. Maddocks, MD, Christian Buske, MD PhD, Sumeet Ambarkhane, MD MBBS, Wolfram Brugger, Maren Dirnberger-Hertweck, PhD, Sascha Tillmanns, Johannes Weirather, PhD, Kristie Blum
Journal: Blood
Blood (2019) 134 (Supplement_1): 4078.
https://doi.org/10.1182/blood-2019-124297
Published: 2019
Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MDPhD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Aleš Obr, MD, Gianluca Gaidano, MD PhD, Marc Andre, MDPhD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 227.
https://doi.org/10.1182/blood-2018-99-113399
Published: 2018